StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Price to Sales Ratio (P/S) on January 31, 2025

StemRIM Price to Sales Ratio (P/S) is NA on January 31, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

StemRIM 52-week high Price to Sales Ratio (P/S) is 14.60 on February 28, 2024, which is NA below the current Price to Sales Ratio (P/S).
StemRIM 52-week low Price to Sales Ratio (P/S) is 8.42 on June 26, 2024, which is NA below the current Price to Sales Ratio (P/S).
StemRIM average Price to Sales Ratio (P/S) for the last 52 weeks is 11.41.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years